Vaccinia virus is the focus of much attention as a vector for expression systems, gene delivery, vaccination, and as a model for viral pathogenesis. However, a major limitation in the ability to utilize vaccinia vectors are concerns about pathogenicity. The study of how vaccinia spreads and evades the host immune response as well as ways to enhance the immunogenicity of expressed antigens, is thus essential for the effective utilization of this vector system. The vaccinia B5R gene encodes a 42-kDa protein found on the membranes of extracellular virions and infected cells. In preliminary studies, we have shown that B5R plays a critical role in cell-to-cell spread and long range dissemination of the virus through the formation of the extracellular enveloped virus (EEV). In addition, the B5R extracellular domain contains repeat units, homologous to complement regulatory proteins, which may be involved in viral evasion of host immune responses. However, we showed that both this domain and the cytoplasmic tail are dispensable for EEV formation and therefore may be utilized as sites for heterologous antigen expression. We hypothesize that B5R is a multifunctional protein that plays a central role in vaccinia pathogenesis, dissemination, and evasion of host immune responses; that by modification of B5R, these in vivo properties of vaccinia can be altered; and that B5R can be manipulated to traffic heterologous antigens to EEV resulting in vaccinia vectors that generate enhanced immunity.
The aim of this study is to better understand the multifunctional B5R protein in vaccinia pathogenesis and exploit it for heterologous protein expression in order to create vaccinia-based vaccines with novel biological and antigen presentation capabilities. To do this we will: 1) define the functional significance of B5R domains for vaccinia pathogenesis in vivo; 2) identify the complement regulatory properties of B5R; and 3) Determine the immune responses generated to novel vaccinia vaccines engineered to express an HIV antigen fused to B5R. We anticipate that these studies will give insight into vaccinia pathogenesis and the role of B5R in dissemination and evasion of host immune responses; provide a mechanism of modulating the pathogenicity of vaccinia vectors; and offer unique approaches to vaccinia-based antigen expression that can be exploited for novel vaccine strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047237-04
Application #
6732771
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Challberg, Mark D
Project Start
2001-06-01
Project End
2006-04-30
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
4
Fiscal Year
2004
Total Cost
$356,625
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Girgis, Natasha M; Dehaven, Brian C; Fan, Xin et al. (2008) Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J Virol 82:4205-14
Viner, Kendra M; Girgis, Natasha; Kwak, Heesun et al. (2007) B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals. Virology 361:356-63
Sfyroera, Georgia; Katragadda, Madan; Morikis, Dimitrios et al. (2005) Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol 174:2143-51
Viner, Kendra M; Isaacs, Stuart N (2005) Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 7:579-83
Kwak, Heesun; Mustafa, Waleed; Speirs, Kendra et al. (2004) Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion. Virology 322:337-48
Isaacs, Stuart N (2004) Working safely with vaccinia virus: laboratory technique and the role of vaccinia vaccination. Methods Mol Biol 269:1-14
Isaacs, Stuart N; Argyropoulos, Emelia; Sfyroera, Georgia et al. (2003) Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 77:8256-62
Mastellos, Dimitrios; Morikis, Dimitrios; Isaacs, Stuart N et al. (2003) Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res 27:367-86
Amorosa, Valerianna K; Isaacs, Stuart N (2003) Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome. Clin Infect Dis 37:426-32
Isaacs, S N (2002) Critical evaluation of smallpox vaccination for laboratory workers. Occup Environ Med 59:573-4

Showing the most recent 10 out of 11 publications